Engineering the future of medicine with composite programmable therapeutics.

Safer Therapies Across Modalities, from Antivirals to Genetic Medicines

Composite programmable therapeutic technology supports drug development for many indications. This is the next generation of therapies designed to treat and cure, and supporting better responses with less side effects.

As validation, we deployed our technology to develop a pipeline of antiviral therapeutics and have successfully constructed candidates that are effective against multiple viruses. Our lead anti-influenza candidate remains effective where other treatments failed, improves survival rates in vivo, and shows excellent distribution and immune-silent properties in mice. Recognizing the global need for cures of virus diseases, we continue to push an antiviral program together with partners.

Through extensive R&D and validation, results like these highlight a universal ability to design potent, targetable, and safe medicines from the ground up via composite programmable therapeutic technology.

We have now shifted our focus towards solving a critical challenge in genetic medicine: the safe and precise delivery of genes. Using a proprietary non-viral vector platform, we enable the safe and precise delivery of genes to support breakthrough genetic medicine applications such as in vivo CAR-T therapies.